Drug Type Small molecule drug |
Synonyms GRL-0920 |
Target |
Mechanism SARS-CoV-2 3CLpro inhibitors(SARS-CoV-2-3C-like-proteinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC14H9ClN2O2 |
InChIKeyBOSZJNSICHFHMA-UHFFFAOYSA-N |
CAS Registry1087243-14-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Preclinical | JP | 25 Aug 2020 | |
Severe Acute Respiratory Syndrome | Preclinical | US | 01 Oct 2008 |